热门资讯> 正文
周五报道，Foghorn Therapeutics获得5000万美元股权融资，推进肿瘤学管道，并将2.089亿美元现金流延长至2028年上半年
2026-01-12 16:37
- Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026
- Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
- Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026
- Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; tracking to IND-enabling studies in 2026
- Strong balance sheet with cash, cash equivalents, and marketable securities of $208.9 million*, including proceeds from the equity financing, which is anticipated to close on January 13, 2026, and allows for continued investment in the pipeline and extends cash into the first half of 2028
推荐文章
美股机会日报 | 美国1月“小非农”不及预期！礼来绩后一度大涨10%，财报强劲超预期
华盛早报 | 辟谣！税收传闻不实；“AI抢饭碗”引抛售潮！纳指跌近1.5%；黄金、白银暴力反弹，华尔街坚定看多
全面甩卖软件股！美股爆发AI恐慌，Anthropic掀起SaaS抛售潮
财报速递 | 超微电脑盘后一度涨逾10%！强劲业绩展望预示AI需求增长
美股机会日报 | 贵金属“大逆转”！金银价再度大涨，机构建议市场回稳再进场；闪迪盘前续涨4%，年内已累涨180%
金银暴跌后“暴力”反弹！华尔街坚定看多：逻辑未破，黄金牛市仍未结束（附相关标的）
抢跑1.5万亿美元造富神话！如何在IPO前投资SpaceX？最全攻略来了
新股申购 | “全球锂电设备龙头”先导智能今起招股！引入欧万达基金等基石投资者
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
